Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumors
NCT05262491Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izalontamab brengitecan in gastrointestinal tumor, solid tumor and triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
gastrointestinal tumorsolid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05262491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262491.